返回 A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® NeuroTech Attends CINS 2017

[2018-01-08] 

Beijing, China - MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech") recently attended the 3rd Annual Conference of Chinese Interventional Neuroradiology Society of Chinese Stroke Association ("CINS 2017"). As one of the most influential academic congresses in the field of neurointervention, the CINS 2017 invited renowned domestic and international neurointervention experts to participate in the case contest and share the latest academic achievements.
The opening speech was chaired by Professor Xinjian Yang of Beijing Tiantan Hospital. Professor Zhongrong Miao, Chairman of the CINS 2017, delivered the opening speech in which he showed his determination to learn from the hard-work spirit of neurointerventional experts to contribute to the development of China's neurointervention industry. Professor Zhongxue Wu of Beijing Tiantan Hospital expressed his expectation on behalf of senior neurointional professionals, encouraging the experts in attendance to find better solutions for the treatment of stroke with joint efforts.
 
During the congress, Professor Liangfu Zhu of Henan Provincial People's Hospital delivered a speech of the application of balloon dilation stent in acute artery occlusion, in which he shared his clinical experience in APOLLO Intracranial Stent System ("APOLLO") and had in-depth discussion with experts in attendance. Professor Zhu analyzed the advantages of APOLLO with high recognition in its safety and efficacy. He also shared the tips and tricks in using the device.
 
APOLLO was designed for the treatment of ischemic cerebrovascular disease. It was first approved by China Food and Drug Administration in 2004. It was China's first intracranial stent for the treatment of ischemic cerebrovascular disease caused by symptomatic intracranial atherosclerotic disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009, named Shanghai Key New Product in 2010, and then listed in the National Key New Product Scheme in 2011. In the future, MicroPort® NeuroTech will continue to devote itself to innovation to provide more safe and effective products and solutions for patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2018 MicroPort Scientific Corporation

CONTACT:
Amanda Zhang
Corporate Culture & Public Relations Director
Shanghai MicroPort Medical (Group) Co., Ltd. (HQ)
Tel: (86)(21) 38954600-6989
Email: spokesperson@microport.com

 

[Prev]:MicroPort® CardioFlow Attends 2017 PCR-CIT China Chengdu Valves
[Next]:MicroPort® Orthopedics Holds the Third TKA Training Course in Hong Kong